Veru Reaches Full Enrollment for Phase 2B Quality Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results
Veru完成肥胖症恩妥珊胺20億質量臨床研究的招募,並報告2024財年第三季度財務結果。
Veru Reaches Full Enrollment for Phase 2B Quality Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results
Veru完成肥胖症恩妥珊胺20億質量臨床研究的招募,並報告2024財年第三季度財務結果。
譯文內容由第三人軟體翻譯。